Artificial Intelligence driven Marketing Communications
A new market study, titled “Discover Global Acute Myeloid Leukaemia Therapeutics Market Upcoming Trends, Growth Drivers and Challenges” has been featured on WiseGuyReports.
Acute myeloid leukemia is a type of cancer that affects blood and bone marrow. Acute myeloid Leukemia therapeutics refers to medical services specializing in the treatment and cure of Acute Myeloid. It is a rare and serious disease commonly found in men over 45 years of age. The five-year survival rate of people with Acute myeloid leukemia is 27%. It is treatable by chemotherapy with or without stem cell transplantation. Approximately, 10,590 people died in the USA alone in 2017 due to Acute myeloid leukemia.
The report provides insights into the global Acute myeloid leukemia therapeutics market on a global, regional and company level. The report also covers the global R&D in the Acute myeloid leukemia therapeutics industry. Crucial opportunities for new players about to enter the market are also included in the report. The restraints in the industry, which are hindering faster growth are also discussed in the report.
Key Players of Global Acute Myeloid Leukaemia Therapeutics Market =>
The global Acute myeloid leukemia therapeutics market is analyzed primarily on the basis of 2 key segments. These key segments are further split into smaller sub-segments.
Close to 21,380 people were reported to be suffering from Acute myeloid leukemia in the USA in 2017. Acute myeloid leukemia accounted for 1.3% of all the cancer patients in the USA. Regionally, the North American region accounted for the highest number of clinical trials. The USA accounted for the highest number of clinical trials as a country globally. The ageing population around the world, along with huge investments from major private players and governments will drive the Acute myeloid leukemia therapeutics market in the future.
On November 22 2019, Celyad, a biopharmaceutical company, reported that it received a grant of $9.3 million for focusing on the development of CYAD-01 and CYAD-02 which are used to treat relapsed/refractory acute myeloid leukemia. These funds will also be utilized in developing next-generation approaches in the treatment of this disease. More investments such as these and the ageing global population will drive the Acute myeloid leukemia therapeutics market further in future.
Major Key Points of Global Acute Myeloid Leukaemia Therapeutics Market
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.